Biophytis S.A.

Equities

ALBPS

FR001400OLP5

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:11 2024-07-12 am EDT			5-day change	1st Jan Change
0.58 ^EUR	+0.87%		0.00%	-71.57%

Jul. 12	BIOPHYTIS : Invest Securities confirms its recommendation	CF
Jul. 11	Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	MT

Biophytis S A : Combined General Meeting of June 24, 2024

June 07, 2024 at 02:32 am EDT

Combined General Meeting of June 24, 2024

07 Jun 2024 08:23 CEST

Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1260881_2024_06_07__PR_CGM_June_24_2024.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Attachments

Original Link
Permalink

Disclaimer

Biophytis SA published this content on 07 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2024 06:31:05 UTC.

Latest news about Biophytis S.A.

BIOPHYTIS : Invest Securities confirms its recommendation	Jul. 12	CF
Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	Jul. 11	MT
Biophytis: approval for a clinical trial in the USA	Jul. 11	CF
Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity	Jul. 11	CI
Biophytis SA Presents Roll-Out and Results of Its Phase 2-3 Cova Study Results in Severe Forms of Covid-19 At the World Congress on Infectious Diseases	Jul. 01	CI
Biophytis: cash position strengthened, share price soars	Jun. 20	CF
Biophytis Extends Bond Financing Deal with Investment Fund Atlas	Jun. 20	MT
Biophytis S.A. Grants Blanver Exclusive Rights to Bio101 in Latin America in Deal Valued At Up to ?108 Million	Jun. 20	CI
Biophytis S.A. Announces the Successful Industrial Transfer of Bio101 (20-Hydroxyecdysone) Production by Its Service Provider Seqens	Jun. 14	CI
Biophytis Files Investigational New Drug Application with US FDA for Mid-stage Obesity Drug Trial	Jun. 10	MT
Biophytis: application filed in obesity in the USA	Jun. 10	CF
Biophytis SA Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity	Jun. 10	CI
Biophytis unveils design for obesity study	May. 14	CF
Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity	May. 14	CI

Chart Biophytis S.A.

Duration

Period

More charts

Company Profile

Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19. The company is located in Paris, France and Cambridge, Massachusetts.

Sector

Biotechnology & Medical Research

Calendar

2024-10-28 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BIOPHYTIS S.A.	-71.57%	3.32M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs

Biophytis S.A.

Equities

ALBPS

FR001400OLP5

Biotechnology & Medical Research

Biophytis S A : Combined General Meeting of June 24, 2024

Latest news about Biophytis S.A.

Chart Biophytis S.A.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs